Drug intelligence / Profile preview

CI-135 CAR-T cells

Development stage: Phase 1
Lead developer: Beijing Boren Hospital
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CI-135 CAR-T cells is a chimeric antigen receptor (CAR) T-cell therapy designed to target FMS-like tyrosine kinase 3 (FLT3), which is being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML). The therapy involves collecting a patient's peripheral blood mononuclear cells (PBMC), engineering them to express the CI-135 CAR construct that targets FLT3, and then infusing these modified T cells back into the patient after lymphodepletion.

Other names: human derived anti-CI135 CAR-T injectionFLT3-targeted CAR-T cell therapyFLT-3-targeted CAR-T cell therapyFLT 3-targeted CAR-T cell therapy

Targets

FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on CI-135 CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CI-135 CAR-T cells.

Explore the full profile